Back to dashboard
CommercialPrior AuthHigh impact

Medical Policy and Coding Updates - April 2022

Premera Blue Cross·WA · Oncology, Rheumatology, Dermatology +4 more·Medical Policy
Effective date
Apr 1, 2022
We identified it
Jun 18, 2026
Days to comply

Summary

Premera Blue Cross updated multiple policies effective April 1, 2022, with additional changes through July 7, 2022. Key changes include new prior authorization requirements for various drugs and procedures, coverage changes for cancer treatments, and updates to autoimmune disease therapies including new atopic dermatitis treatments.

Action Required

Action needed
Immediately: Update billing system to require prior authorization for codes J9273, J9359, J0219, J0879, J0491, C9093, Q5124, and genetic testing codes 0306U-0320U. Mark codes H2038, T2050, T2051 as non-covered. Update investigational review requirements for amniotic membrane codes Q4224, Q4225, Q4256, Q4257, Q4258 and bioengineered skin substitute codes A2011, A2012, A2013. Remove terminated codes C9084, C9085, C9086 from system. Notify providers of new atopic dermatitis drug coverage and reduced trial requirements for Dupixent.

Affected Billing Codes

Q4224
Q4225
Q4256
Q4257
Q4258
J9273
J9359
A2011
A2012
A2013
C9090
J0219
J0879
C9091
H2038
T2050
T2051
K1028
K1029
J0491
A9291
C9093
Q5124
E0761
C9084
C9085
C9086
Q5109